Developments in the Wet AMD Treatment Landscape

This program will include a discussion of off-label treatment, investigational agents and devices not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Current Treatments for Wet AMD Pan-VEGF-A Blockers

How Effective Are Current Treatments?

Treatment Approaches Impacts of Individualized vs Monthly Treatments

Individualized Treatment Strategies in Practice

Challenge of Undertreatment

Seeking Better Outcomes Diagnostic Tests: PHP

Seeking Better Outcomes Diagnostic Tests: OCTA

Challenge of Treating Refractory Wet AMD

Unmet Needs Patient Improvement and Therapeutic ‘Wish List’

Emerging Treatments Therapeutic Targets

New and Emerging Anti-VEGF Blockers

Brolucizumab Phase 3 Studies: HAWK and HARRIER

Abicipar

Conbercept

OPT-302

ICON-1

Anti-Angiopoetin-2 Agents

TKIs: Therapeutic Swing and Miss?

Integrin Antagonists

Sustained Delivery Methods PDS

Sustained Delivery Method Injectable Delivery

Gene Therapy

Gene Therapy (cont)

Is Prevention Possible?

Concluding Remarks

Abbreviations

Abbreviations (cont)